Skip to main content
. 2014 Oct 2;143(3):416–427. doi: 10.1111/imm.12319

Figure 3.

Figure 3

Activity of bifunctional interleukin-4 (IL-4)/IL-13 antagonist in oxazolone-induced colitis model. Groups of 15 female SJL/J mice were sensitized with oxazolone painted on the skin on Day −5, then challenged intrarectally with oxazolone on Day 0. Starting the day before intrarectal challenge (Day −1), mice were administered bifunctional antagonist at 8, 2, or 0·5 mg/kg intraperitoneally, every 2 days. Control animals were given oxazolone but no treatment (OXA), were given OXA and treated with mouse IgG2a control, or had no disease induction (no OXA). (a) On Days 1–7, the animals were scored for body weight. At time of kiling on Day 8, colons were excised. (b) Morphology of colons at death. Representative colons are shown from animals given OXA but no treatment (OXA), those given OXA and treated with bifunctional IL-4/IL-13 antagonist (8 mg/kg) or animals that had no disease induction (no OXA). (c) Colon weight, (d) colon length; (e) ratio of colon weight/length; and (f) disease activity index (average over the 7-day study) are shown as indicators of disease severity. P-values were determined by t-test in comparison with the mouse IgG2a-treated control group.